Has Sandesh Parajuli received payments from drug or device companies?

Yes. Drug and device makers reported $11,726 in general payments to Sandesh Parajuli across 22 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Sandesh Parajuli did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Sandesh Parajuli come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Sandesh Parajuli

Nephrology · Madison, WINPI 1184861718

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (55.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Amgen accounts for 74.0% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $5,272, more than ten times the $230 reported in 2019. Among nephrology clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$11,726in general payments, 2019–2025

Across 22 payments — averaging $533.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$9K
Calliditas Therapeutics US Inc.$2K
Veloxis Pharmaceuticals, Inc.$186
Travere Therapeutics, Inc.$132
Akebia Therapeutics Inc$125
Mallinckrodt Enterprises LLC$100
plus $61 from 1 others

$675,135in research payments, 2019–2025

Across 148 payments — averaging $4561.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Merck$269K
CSL Behring$192K
Nobelpharma America, LLC$112K
Veloxis Pharmaceuticals, Inc.$101K

What the payments were for

Consulting fees$6,49055%
Speaking & faculty fees$3,24028%
Travel & lodging$1,0259%
Food & beverage$6906%
Education$2812%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen(2 entities)	13	$8,672
Calliditas Therapeutics US Inc.	2	$2,450
Veloxis Pharmaceuticals, Inc.	3	$186
Travere Therapeutics, Inc.	1	$132
Akebia Therapeutics Inc	1	$125
Mallinckrodt Enterprises LLC	1	$100
Novartis	1	$61

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

KRYSTEXXA$8,068
TARPEYO$2,400
Envarsus$250
AURYXIA$125
Vafseo$125

How this compares

$11,726 in reported general payments places this provider in the 90th percentile of 173 nephrology providers in Wisconsin.

See all nephrology providers in Wisconsin →

Medicare billing

Part B allowed, 2024

$48,523

Medicare patients

257

Services billed

808

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
ProcritEpoetin Alfa	11	$43,160
Envarsus XrTacrolimus	16	$22,740
Cinacalcet Hcl	90	$9,125
Valganciclovir Hcl	13	$6,219
Tacrolimus	68	$5,537
Mycophenolic AcidMycophenolate Sodium	40	$4,419
Nifedipine ErNifedipine	171	$4,120
Prednisone	521	$2,748
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim	194	$1,519
Carvedilol	196	$1,328
Pantoprazole Sodium	127	$986
Metoprolol Succinate	76	$899
Omeprazole	38	$896
Losartan Potassium	82	$854
Tamsulosin Hcl	81	$798

Paid to pharmacies, not to this prescriber.

Other nephrology in Madison

Didier MandelbrotMadison$7K
Sayee Sundar AlagusundaramoorthyMadison$6K
Andrey VavrenyukMadison$2K
Gabino Maza RodasMadison$1K
Nolan InterialMadison$815
Kevin RegnerMilwaukee$246K
Rosanna RanieriKenosha$84K
Micah ChanFitchburg$80K
Rishi KoraGlendale$57K
Manohar AhujaMilwaukee$35K

See the full list for Wisconsin →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →